EUVIMEDEUVIMED entdecken
Crossref

Long‐Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice

Xia Chuai, Tianxi Ye, Baoxin Zhao, Yan Wu, Chen Guo, Fangxu Li, Jinge Zhou, Kaiyue Zhang, Yuping Wang, Yanhui Liu, Yalin Xie, Jiancun Zhang und 1 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Xia Chuai und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, China. Hauptthemen laut MEDLINE: Vaccinia virus, mRNA Vaccines, Antibodies, Viral, Mice, Inbred BALB C. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB0490000), the National Key Research and Dev….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The outbreak of clade II monkeypox virus (MPXV) and the additional outbreak in Central Africa of clade I virus from 2023 have attracted worldwide attention. The development of a scalable and effective vaccine against the ongoing epidemic of mpox is urgently needed. We previously constructed two bivalent MPXV mRNA vaccines, LBA (B6R‐A29L) and LAM (A35R‐M1R), and a quadrivalent mRNA vaccine, LBAAM (B6R‐A35R‐A29L‐M1R). These vaccines at a 20 µg dose could induce potential MPXV antigen‐specific immune responses and provide protection against lethal VACV challenge. Compared with the individual bivalent mRNA vaccines, the two quadrivalent vaccines LBAAM and LBA& LAM displayed superior protective effects. To characterize these vaccines further, we monitored long‐term immunity and protection as long as 28 weeks after initial immunization and optimized the immunization dosages to decrease the cost of production for future clinical use. Our results demonstrated that both the bivalent MPXV mRNA vaccine LAM (A35R‐M1R) and the two tetravalent vaccines LBAAM and LBA& LAM could elicit long‐lasting antigen‐specific IgG antibodies as well as neutralizing antibodies against VACV and MPXV. They all provided complete protection against VACV challenge until 28 weeks post prime immunization. Moreover, the immunogenicity and protective efficacy of the two tetravalent vaccines (LBAAM and LBA& LAM) are dose dependent, and even the low‐dose (1 µg) vaccine could provide sufficient protection against lethal VACV challenge. These results provide valuable clues for the further production of MPXV mRNA vaccines for use in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccinia virusmRNA VaccinesAntibodies, ViralMice, Inbred BALB CAntibodies, NeutralizingAnimalsMiceFemaleMpox, MonkeypoxVaccines, SyntheticMonkeypox virusVacciniaDisease Models, AnimalViral VaccinesVaccine Efficacy

Stichwörter der Autor:innen

MPXVdoselong‐term protectionmRNA vaccine

Substanzen

mRNA VaccinesAntibodies, ViralAntibodies, NeutralizingVaccines, SyntheticViral Vaccines

Autor:innen und Institutionen

  • State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Guangzhou Henovcom Bioscience Co. Ltd., Guangzhou, China.
  • State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, China.

Förderung

  • This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB0490000), the National Key Research and Dev…

Zitieren

APA

Chuai, X., Ye, T., Zhao, B., Wu, Y., Guo, C., Li, F., Zhou, J., Zhang, K., Wang, Y., Liu, Y., Xie, Y., Zhang, J., & Chiu, S. (2025). Long‐Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice. Journal of Medical Virology. https://doi.org/10.1002/jmv.70143

Vancouver

Chuai X, Ye T, Zhao B, Wu Y, Guo C, Li F, et al. Long‐Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice. Journal of Medical Virology. 2025. doi:10.1002/jmv.70143

BibTeX
@article{Chuai2025,
  author = {Chuai, Xia and Ye, Tianxi and Zhao, Baoxin and Wu, Yan and Guo, Chen and Li, Fangxu and Zhou, Jinge and Zhang, Kaiyue and Wang, Yuping and Liu, Yanhui and Xie, Yalin and Zhang, Jiancun and Chiu, Sandra},
  title = {Long‐Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70143}
}
Kostenlos starten →